WALVAX(SZ:300142) Xin Lang Zheng Quan·2026-01-30 01:26Core Viewpoint - Watson Bio's stock experienced a decline of 1.15% on January 29, with a trading volume of 908 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On January 29, Watson Bio had a financing buy-in amount of 90.98 million yuan and a financing repayment of 114 million yuan, resulting in a net financing outflow of 22.56 million yuan [1]. - As of January 29, the total financing and securities lending balance for Watson Bio was 1.633 billion yuan, with the financing balance at 1.619 billion yuan, accounting for 7.86% of the circulating market value, which is below the 10% percentile level over the past year [1]. - In terms of securities lending, Watson Bio repaid 700 shares and sold 2,600 shares on January 29, with a selling amount of 33,500 yuan, while the remaining securities lending volume was 1.0936 million shares, with a balance of 14.0959 million yuan, exceeding the 90% percentile level over the past year [1]. Business Performance Summary - As of September 30, Watson Bio had 114,000 shareholders, a decrease of 2.75% from the previous period, while the average circulating shares per person increased by 2.83% to 13,643 shares [2]. - For the period from January to September 2025, Watson Bio reported an operating income of 1.719 billion yuan, a year-on-year decrease of 19.73%, and a net profit attributable to shareholders of 163 million yuan, down 36.24% year-on-year [2]. - Since its A-share listing, Watson Bio has distributed a total of 451 million yuan in dividends, with 95.96 million yuan distributed over the past three years [2]. Institutional Holdings Summary - As of September 30, 2025, the largest circulating shareholder of Watson Bio was E Fund's ChiNext ETF, holding 34.4714 million shares, a decrease of 5.8005 million shares from the previous period [2]. - The sixth largest circulating shareholder was Southern CSI 500 ETF, holding 23.2821 million shares, down by 530,100 shares compared to the previous period [2]. - The eighth largest circulating shareholder was the China National Bio-Medical Index A, holding 23.0678 million shares, a decrease of 390,870 shares from the previous period, while Hong Kong Central Clearing Limited, the tenth largest shareholder, increased its holdings by 233,600 shares to 20.2008 million shares [2].